Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7563874B2 · kind B2 · utility
25Cited by
22References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2003 |
| Grant date | Jul 21, 2009 |
| Priority date | — |
| Expiry date | Aug 14, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.